New breathing tech aims to free ICU patients from ventilators faster

NCT ID NCT05219643

Completed Disease control Sponsor: Southeast University, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a newer breathing support method called NAVA helps patients with ARDS come off mechanical ventilation faster than standard PSV. 130 tracheotomy patients were randomly assigned to one of the two methods. The main goal was to see how many days patients were alive and free from the ventilator within 28 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NAVA (neurally-adjusted ventilatory assist) device
What this could lead to: If successful, NAVA could become a standard method to help patients with ARDS breathe on their own faster, reducing time on a ventilator.
What could go wrong: This is a completed trial with 130 participants, so results are limited. NAVA may not improve weaning success or ICU outcomes compared to standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARDS

Contacts and locations

Locations

Yijishan Hospital, The First Affiliated Hospital of Wannan Medical College

Wuhu, Anhui, 241001, China
Zhongda Hospital

Nanjing, Jiangsu, 210009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.